Compounds > fagaramide
Page last updated: 2024-12-10

fagaramide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5281772
CHEMBL ID252709
CHEBI ID4966
SCHEMBL ID2987846
SCHEMBL ID17073972
MeSH IDM0104525

Synonyms (37)

Synonym
HMS1750A04
AKOS001133721
2-propenamide, 3-(1,3-benzodioxol-5-yl)-n-(2-methylpropyl)-, (2e)-
(e)-3-(1,3-benzodioxol-5-yl)-n-isobutyl-prop-2-enamide
nsc-94257
cinnamamide,4-(methylenedioxy)-, stereoisomer
nsc94257
cinnamamide,4-(methylenedioxy)-
2-propenamide,3-benzodioxol-5-yl)-n-(2-methylpropyl)-, (e)-
495-86-3
fagaramide
chebi:4966 ,
CHEMBL252709
fogaramide
trans-fagaramide
3-(1,3-benzodioxol-5-yl)-n-(2-methylpropyl)prop-2-enamide
AC1NQZ1T ,
(e)-3-(1,3-benzodioxol-5-yl)-n-(2-methylpropyl)prop-2-enamide
c2uhl92kkp ,
cinnamamide, n-isobutyl-3,4-(methylenedioxy)-, (e)-
cinnamamide, n-isobutyl-3,4- (methylenedioxy)-
n-isobutyl-3,4-methylenedioxycinnamamide
60045-88-7
3-(1,3-benzodioxo-5-yl)-n-(2-methylpropyl)-2-propenamide
2-propenamide, 3-(1,3-benzodioxol-5-yl)-n-(2-methylpropyl)-
ai3-30755
piperonyl-4-aacrylylisobutylamide
cinnamamide, n-isobutyl-3,4-methylenedioxy-
SCHEMBL2987846
fagaramid
t5404670
SCHEMBL17073972
(2e)-3-(1,3-benzodioxol-5-yl)-n-isobutyl-2-propenamide
Z32386287
Q27106593
DTXSID001318385
n-isobutyl-3,4-methylenedioxy cinnamide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
cinnamamidesAn enamide which is cinnamamide or a derivative of cinnamamide obtained by replacement of one or more of its hydrogens.
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1172777Toxic CNS activity in C57BL/6 mouse assessed as locomotor activity by measuring exploratory activity counts at 10 mg/kg, ig by open-field test (Rvb = 94.50 +/- 6.18 counts)2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Synthesis and structure-activity relationship of novel cinnamamide derivatives as antidepressant agents.
AID400739Insecticidal activity against housefly at 2500 ppm after 3 to 5 days1998Journal of natural products, May, Volume: 61, Issue:5
Novel and insecticidal isobutylamides from dinosperma erythrococca
AID400744Insecticidal activity against tobacco budworm at 2500 ppm after 3 to 5 days1998Journal of natural products, May, Volume: 61, Issue:5
Novel and insecticidal isobutylamides from dinosperma erythrococca
AID1172778Antidepressant activity in C57BL/6 mouse assessed as decrease in immobility duration at 10 mg/kg, ig by tail suspension test2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Synthesis and structure-activity relationship of novel cinnamamide derivatives as antidepressant agents.
AID311533Cytotoxicity against mouse RAW cells2007Journal of natural products, Oct, Volume: 70, Issue:10
Trypanocidal and antileishmanial dihydrochelerythrine derivatives from Garcinia lucida.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (16.67)18.7374
1990's1 (16.67)18.2507
2000's1 (16.67)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.35 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
fluoxetine
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.		2.110(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound
pentamidine
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.		2.0310aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic
suramin
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.		2.0310naphthalenesulfonic acid;
phenylureas;
secondary carboxamide		angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
sesamin
(+)-sesamin : A lignan that consists of tetrahydro-1H,3H-furo[3,4-c]furan substituted by 1,3-benzodioxole groups at positions 1 and 4 (the 1S,3aR,4S,6aR stereoisomer). Isolated from Cinnamomum camphora, it exhibits cytotoxic activity.		2.0310benzodioxoles;
furofuran;
lignan		antineoplastic agent;
neuroprotective agent;
plant metabolite
6-acetonyldihydrochelerythrine
6-acetonyldihydrochelerythrine: from formosan Argemone mexicana; structure in first source		2.0310
dihydrochelerythrine
dihydrochelerythrine: trypanocidal and antileishmanial dihydrochelerythrine derivative from Garcinia lucida; structure in first source		2.0310benzophenanthridine alkaloid
pellitorine
pellitorine: consists of piper sylvaticum Roxb.; structure		1.9910fatty amidemetabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610